Protective Equipment Infused with Antiviral Properties for Future Pandemics

Rare immune mutation found by scientists, potentially forming basis for universal antiviral remedy, discovered only in a few dozen individuals globally.

, and Administrator

2025 September 3 . 6:50 AM

2 min read

Protection Gear Against Future Viral Outbreaks

Protective Equipment Infused with Antiviral Properties for Future Pandemics

In the realm of medical research, a groundbreaking antiviral treatment is making waves, reminiscent of a plot from a sci-fi movie. This innovative solution, currently under development, is based on the immune response of people with ISG15 immunodeficiency, a rare genetic condition that affects the immune system.

ISG15 immunodeficiency, while present in a few dozen people worldwide, offers an intriguing twist. People with this condition have an immunity to known viruses, a fact that has caught the attention of researchers. The constant, mild inflammation experienced by those with ISG15 immunodeficiency is believed to be at the root of their immunoresponse.

The new antiviral treatment is designed to stimulate the production of the 10 most beneficial proteins from the natural mutation using 10 mRNA sequences inside a lipid nanoparticle. This method, if successful, could potentially be used as an intranasal vaccine, offering a proactive approach against viral infections.

If this antiviral treatment proves successful in human trials, it could be administered before new targeted vaccines are developed for the next pandemic, providing a much-needed layer of protection for first responders as a form of biological Personal Protective Equipment (PPE).

Lead researcher Dusan Bogunovic is optimistic about the treatment's potential, stating that it has yet to be broken by any virus. The treatment is designed to be effective against a wide range of viruses, including potential unknown ones, making it a potential game-changer in the fight against infectious diseases.

However, it's important to note that while there is emerging research on antiviral strategies inspired by ISG15 deficiency involving mRNA technologies that protect against viral infections in vitro and in vivo, specific details on the mechanism of action and plans for intranasal vaccine administration in human trials have not yet been reported or publicly disclosed as of August 2025. Further official publications or clinical trial announcements will be needed to clarify these points.

In conclusion, the development of this universal antiviral treatment, inspired by the immune response of people with ISG15 immunodeficiency, represents a significant leap forward in the field of medical research. Its potential to provide protection against a wide range of viruses, including unknown ones, could revolutionise the way we approach viral infections, offering hope for a future where pandemics are met with proactive, effective solutions.